BACKGROUND: Elevated C-reactive protein (CRP) may contribute to elevated arterial pressure in Ang II-dependent hypertension. However, the in vivo effects of Ang II and of mineralocorticoid receptor (MR) antagonism on CRP during Ang II-dependent hypertension have not been examined. In addition, urinary CRP excretion as a method to monitor the progression of Ang II-induced inflammation has not been evaluated. METHODS: Urine samples were collected from three groups (n = 10/group) of rats: 1) normotensive control, 2) angiotensin II infused (Ang II; 60 ng/min), and 3) Ang II + eplerenone (epl; 25 mg/d). A diet containing epl (0.1 %) was provided after 1 week of Ang II infusion. RESULTS: After 28 d, Ang II increased SBP from 136 +/- 5 to 207 +/- 8 mmHg; this response in SBP was not altered following MR antagonism (215 +/- 6 mmHg). Ang II-infusion increased plasma CRP from 14 +/- 2 to 26 +/- 3 mug/mL and increased urinary CRP excretion nearly 8-fold (143 +/- 26 vs 1102 +/- 115 ng/d). Treatment with eplerenone reduced plasma CRP by 25 % and urinary immunoreactive CRP (irCRP) by 34 % in Ang II-infused rats suggesting that aldosterone contributes to the CRP-associated inflammatory response in Ang II-dependent hypertension. CONCLUSIONS: The increase in SBP preceded the increase in irCRP excretion by at least 4 days suggesting that CRP does not significantly contribute to increased arterial blood pressure in Ang II-dependent hypertension. The blockade of MR reduced plasma CRP and urinary irCRP excretion demonstrating the contribution of aldosterone to the Ang II-induced generation of CRP. Furthermore, urinary CRP may serve as a non-invasive index for monitoring cardiovascular inflammation during hypertension.
BACKGROUND: Elevated C-reactive protein (CRP) may contribute to elevated arterial pressure in Ang II-dependent hypertension. However, the in vivo effects of Ang II and of mineralocorticoid receptor (MR) antagonism on CRP during Ang II-dependent hypertension have not been examined. In addition, urinary CRP excretion as a method to monitor the progression of Ang II-induced inflammation has not been evaluated. METHODS: Urine samples were collected from three groups (n = 10/group) of rats: 1) normotensive control, 2) angiotensin II infused (Ang II; 60 ng/min), and 3) Ang II + eplerenone (epl; 25 mg/d). A diet containing epl (0.1 %) was provided after 1 week of Ang II infusion. RESULTS: After 28 d, Ang II increased SBP from 136 +/- 5 to 207 +/- 8 mmHg; this response in SBP was not altered following MR antagonism (215 +/- 6 mmHg). Ang II-infusion increased plasma CRP from 14 +/- 2 to 26 +/- 3 mug/mL and increased urinary CRP excretion nearly 8-fold (143 +/- 26 vs 1102 +/- 115 ng/d). Treatment with eplerenone reduced plasma CRP by 25 % and urinary immunoreactive CRP (irCRP) by 34 % in Ang II-infused rats suggesting that aldosterone contributes to the CRP-associated inflammatory response in Ang II-dependent hypertension. CONCLUSIONS: The increase in SBP preceded the increase in irCRP excretion by at least 4 days suggesting that CRP does not significantly contribute to increased arterial blood pressure in Ang II-dependent hypertension. The blockade of MR reduced plasma CRP and urinary irCRP excretion demonstrating the contribution of aldosterone to the Ang II-induced generation of CRP. Furthermore, urinary CRP may serve as a non-invasive index for monitoring cardiovascular inflammation during hypertension.
Authors: David Sanz-Rosa; M Pilar Oubiña; Eva Cediel; Natalia De las Heras; Paloma Aragoncillo; Gloria Balfagón; Victoria Cachofeiro; Vicente Lahera Journal: Antioxid Redox Signal Date: 2005 Sep-Oct Impact factor: 8.401
Authors: Valerie Godfrey; Colin A J Farquharson; John E Macdonald; Kok-Meng Yee; Allan D Struthers Journal: Int J Cardiol Date: 2006-08-08 Impact factor: 4.164
Authors: Ryousuke Satou; Martha Franco; Courtney M Dugas; Akemi Katsurada; L Gabriel Navar Journal: Int J Mol Sci Date: 2022-07-12 Impact factor: 6.208